Literature DB >> 15599249

Orbital decompression for gross proptosis associated with orbital lymphangioma.

James Hsuan1, Rahman Malhotra, Garry Davis, Dinesh Selva.   

Abstract

A 14-year-old boy with 11 mm of proptosis and exposure keratopathy secondary to an orbital lymphangioma underwent surgical debulking with a carbon dioxide laser through a lateral orbitotomy combined with a 3-wall orbital decompression. The proptosis was reduced by approximately 2 mm as a result of the debulking procedure, but a further 5 mm reduction was achieved with the orbital decompression. No serious adverse effects were encountered. Bony orbital decompression may be a useful alternative treatment in patients with severe proptosis secondary to orbital lymphangioma.

Entities:  

Mesh:

Year:  2004        PMID: 15599249     DOI: 10.1097/01.iop.0000144790.78416.e7

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  5 in total

1.  Orbital lymphangioma treated by lateral wall decompression and fat removal.

Authors:  Jeong Kyu Lee; Tae Soo Lee
Journal:  Jpn J Ophthalmol       Date:  2010-04-18       Impact factor: 2.447

2.  Neuroimaging in ophthalmology.

Authors:  James D Kim; Nafiseh Hashemi; Rachel Gelman; Andrew G Lee
Journal:  Saudi J Ophthalmol       Date:  2012-10

3.  Sclerosing therapy for orbital lymphangioma using sodium tetradecyl sulfate.

Authors:  Anuchit Poonyathalang; Pisit Preechawat; Pakorn Jiarakongmun; Sirintara Pongpech
Journal:  Jpn J Ophthalmol       Date:  2008-09-05       Impact factor: 2.447

4.  Congenital orbital lymphangioma in a 20-years old girl a case report and review of literature.

Authors:  A Mishra; R Abuhajar; K Alsawidi; M Alaoud; Ef Ehtuish
Journal:  Libyan J Med       Date:  2009-12-01       Impact factor: 1.657

5.  Lymphatic malformations of the orbit.

Authors:  Susanne Wiegand; Behfar Eivazi; Linda M Bloch; Annette P Zimmermann; Andreas M Sesterhenn; Stephan Schulze; Jochen A Werner
Journal:  Clin Exp Otorhinolaryngol       Date:  2013-03-08       Impact factor: 3.372

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.